Swiss pharma firm Roche suffered from exchange rate effects in the first quarter. Sales in the reporting currency, the Swiss franc, were thus below the previous year’s figure after the first three months. +Get the most important news from Switzerland in your inbox Roche generated sales of CHF14.7 billion ($18.7 billion) between January and March. While this represents a decrease of 5% in the reporting currency of Swiss francs, at constant exchange rates there was an increase of 6%. The Group thus met its own target, which is based on constant exchange rates. At CHF11.5 billion (-4%), the Pharmaceuticals Division, as usual, contributed the lion’s share of Group sales. Roche’s diagnostics business generated sales of CHF3.3 billion (-7%). Roche traditionally does not publish profit figures for odd-numbered quarters. Roche’s reported figures are still in line with analysts’ estimates. + Can Swiss pharma giant Roche reshape the obesity market? The management team headed by CEO Thomas …